Global Hyperimmunoglobulin D Syndrome (HIDS) Treatment Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2033

Hyperimmunoglobulin D Syndrome (HIDS) Treatment Market Overview

The Hyperimmunoglobulin D Syndrome (HIDS) Treatment Market was valued at USD 215.00 Million in 2025 and is projected to reach USD 467 Million by 2033, growing at a CAGR of 10.20% from 2026 to 2033. The Hyperimmunoglobulin D Syndrome (HIDS) Treatment Market is experiencing steady growth, driven by increasing awareness of rare autoinflammatory disorders, improvements in genetic and diagnostic testing, and rising focus on targeted biologic and anti-inflammatory therapies. Expanding research into mevalonate kinase pathway deficiencies and the growing pipeline of orphan drugs are further supporting market expansion, as healthcare systems prioritize early and accurate diagnosis to improve long-term patient outcomes.

The rising prevalence of undiagnosed or misdiagnosed periodic fever syndromes, along with stronger government incentives for orphan drug development, is encouraging pharmaceutical companies and research institutions to invest in novel treatment approaches for HIDS. In addition, advancements in precision medicine, biologics, and enzyme-targeted therapies are enabling more effective symptom management, reducing attack frequency, and improving quality of life for patients, thereby accelerating adoption of advanced therapeutic options across major healthcare markets.

Key Market Trends & Insights

• North America dominated the Hyperimmunoglobulin D Syndrome (HIDS) Treatment Market with the largest revenue share of 39.26% in 2025, supported by advanced healthcare infrastructure, strong rare disease awareness programs, and high adoption of biologic and targeted immunotherapies. The region also benefits from robust genetic screening capabilities and favorable orphan drug reimbursement frameworks.
• The Oral segment dominated the market with a share of 17% in 2025, due to high patient compliance, ease of administration, and widespread use of oral analgesics and anti-inflammatory drugs for symptom management.
• Asia-Pacific is expected to be the fastest-growing region in the Hyperimmunoglobulin D Syndrome (HIDS) Treatment Market, projected to register a CAGR of 7.2% from 2026 to 2033. This growth is fueled by rising healthcare awareness, improving rare disease diagnosis rates, expanding healthcare infrastructure, and increasing access to advanced biologics and immunology-based treatments across countries such as China, India, and Japan.
• Medication, the Corticosteroids segment led the market with a 36.74% share in 2025, owing to their widespread use in managing acute inflammatory episodes, while Biologic and targeted therapy options are emerging as the fastest-growing category, reflecting increasing shift toward precision medicine and long-term disease control.
• Route of Administration, the Oral segment dominated the market with a 52.11% revenue share in 2025 due to ease of use and patient compliance, whereas Parenteral administration is expected to be the fastest-growing segment with a CAGR of 6.6%, driven by increasing use of injectable biologics for severe or refractory cases.
• End-Users, Hospitals accounted for the largest share of 58.43% in 2025, supported by availability of specialized care and diagnostic facilities, while Specialty Clinics are witnessing the fastest growth as rare disease treatment centers expand and multidisciplinary care models become more common.

Market Size & Forecast

• Global Market Value (2025): USD 215.00 Million
• Expected Market Value (2033): USD 467 Million
• Forecast CAGR (2026–2033): 10.20%
• Leading Region in 2025: North America
• Fastest Growing Region: Asia-Pacific

Report Scope and Hyperimmunoglobulin D Syndrome (HIDS) Treatment Market Segmentation

Hyperimmunoglobulin D Syndrome (HIDS) Treatment Market Trends

Trend: Growing Focus on Rare Disease Awareness & Advanced Immunology Treatments

The Hyperimmunoglobulin D Syndrome (HIDS) Treatment Market is witnessing increasing clinical attention due to rising awareness of periodic fever syndromes and improved recognition of mevalonate kinase pathway disorders. For instance, HIDS is often misdiagnosed as recurrent infection in early childhood, but the adoption of next-generation sequencing (NGS) panels and inflammatory biomarker profiling (such as elevated IgD and IL-1 activity) is significantly improving diagnostic accuracy. This shift is encouraging earlier therapeutic intervention using biologics like IL-1 inhibitors, improving patient outcomes and reducing long-term inflammatory complications.

Hyperimmunoglobulin D Syndrome (HIDS) Treatment Market Dynamics

Key Market Driver: Rising Adoption of Biologics and Targeted Immunotherapy

The increasing clinical use of targeted biologic therapies is a major driver in the HIDS treatment market. Drugs such as IL-1 inhibitors (e.g., anakinra and canakinumab) are being increasingly prescribed for patients with recurrent inflammatory flares, particularly in Europe and North America, where rare disease registries and reimbursement support are stronger. Clinical studies have shown that IL-1 blockade can reduce attack frequency by over 60–70% in many autoinflammatory patients, driving strong physician preference toward precision immunotherapy. Pharmaceutical companies are also expanding orphan drug pipelines focused on inflammasome-mediated diseases, further accelerating market growth.

Key Restraint/Challenge: Limited Patient Pool and High Diagnostic Delay

A major challenge in the HIDS treatment market is the extremely low prevalence of the disease, estimated at only a few thousand diagnosed cases globally, combined with significant underdiagnosis. Patients often experience a diagnostic delay of 5–10 years due to symptom overlap with other periodic fever syndromes such as Familial Mediterranean Fever. Additionally, high costs associated with genetic testing, biologic therapies, and long-term immunomodulatory treatment limit access in low- and middle-income regions, particularly across parts of Asia-Pacific and Latin America where rare disease infrastructure is still developing.

Key Market Opportunity: Expansion of Genomic Screening and Personalized Medicine Programs

A significant opportunity lies in the expansion of genomic screening programs and precision medicine initiatives. Countries such as the U.S., U.K., and Japan are increasingly integrating whole-exome sequencing into rare disease diagnostic pathways, enabling earlier identification of mevalonate kinase deficiency-related conditions like HIDS. For example, hospital networks in Europe have begun implementing rare disease diagnostic hubs that reduce time-to-diagnosis by nearly 30–40%. In addition, the growing pipeline of IL-1 and IL-6 pathway inhibitors, combined with AI-driven drug repurposing platforms, is expected to expand treatment accessibility and improve clinical decision-making in the coming years.

Hyperimmunoglobulin D Syndrome (HIDS) Treatment Market Scope

The Hyperimmunoglobulin D Syndrome (HIDS) Treatment market is segmented on the basis of diagnosis, medication, route of administration, end-users, and distribution channel.

By Diagnosis

On the basis of diagnosis, the Hyperimmunoglobulin D Syndrome (HIDS) Treatment Market is segmented into Clinical Evaluation, Blood Test, and Others. The Clinical Evaluation segment dominated the market with a share of 46.28% in 2025, due to its widespread use as the first step in identifying recurrent fever patterns, inflammatory flare history, and symptom-based screening in pediatric and adult patients. Many healthcare systems, especially in emerging economies, still rely heavily on clinical judgment because of limited access to advanced molecular diagnostics. The dominance is further supported by delayed genetic confirmation in rare disease pathways and higher dependence on physician-led assessment in primary and secondary care settings. In addition, recurring fever episodes and overlapping symptoms with other autoinflammatory diseases make clinical evaluation the most practical and cost-effective diagnostic approach. Hospitals and general practitioners often initiate treatment based on clinical suspicion before confirmatory testing.

The Blood Test segment is expected to witness the fastest growth at a CAGR of 7.1% from 2026 to 2033, driven by increasing adoption of inflammatory biomarker testing and genetic screening technologies. Elevated IgD levels, CRP, ESR, and cytokine profiling are being increasingly used to support early suspicion of HIDS. Advancements in next-generation sequencing (NGS) panels are improving diagnostic accuracy and reducing misdiagnosis rates. Growing awareness among clinicians about autoinflammatory diseases is accelerating demand for laboratory-based confirmation. In developed markets such as North America and Europe, integrated rare disease testing programs are expanding rapidly. Increasing investment in molecular diagnostics infrastructure is also supporting segment growth. Early and accurate diagnosis is becoming a priority to reduce long-term complications and improve treatment outcomes.

By Medication

On the basis of medication, the market is segmented into Analgesics, Corticosteroids, and Others (including biologics and immunomodulators). The Corticosteroids segment dominated the market with a share of 38.64% in 2025, due to their strong effectiveness in managing acute inflammatory attacks and fever episodes associated with HIDS. These drugs are widely prescribed as first-line therapy in both hospital and outpatient settings for rapid symptom control. Their affordability, easy availability, and established clinical usage contribute significantly to their dominance. Corticosteroids help reduce inflammation during flare-ups, improving patient comfort and reducing hospitalization needs. In many regions, they remain the most accessible treatment option compared to expensive biologics. Physicians often rely on them for short-term management while long-term therapies are evaluated. Their role in emergency symptom suppression further strengthens their market position.

The Biologics & targeted therapy segment is expected to register the fastest CAGR of 7.4% from 2026 to 2033, driven by increasing adoption of precision immunotherapy approaches. IL-1 inhibitors such as anakinra and canakinumab are showing strong clinical outcomes in reducing attack frequency by 60–70% in many patients. Growing preference for disease-modifying therapies over symptomatic relief is accelerating adoption. Pharmaceutical companies are expanding orphan drug pipelines focused on inflammasome-related diseases. Higher healthcare spending in developed regions is improving access to advanced biologics. Clinical guidelines are increasingly recommending targeted therapies for moderate to severe cases. Rising awareness of long-term disease control benefits is further boosting demand.

By Route of Administration

On the basis of route of administration, the market is segmented into Oral, Parenteral, and Others. The Oral segment dominated the market with a share of 52.17% in 2025, due to high patient compliance, ease of administration, and widespread use of oral analgesics and anti-inflammatory drugs for symptom management. Oral medications are preferred for mild to moderate cases where long-term therapy is not required. They are widely available across hospital and retail pharmacies, making them accessible in both developed and emerging regions. Patients often prefer oral treatments for convenience and reduced hospital dependency. Cost-effectiveness also contributes to their dominant market share. Physicians frequently prescribe oral drugs as first-line supportive therapy. Their role in outpatient management strengthens their leadership position in the market.

The Parenteral segment is expected to witness the fastest growth at a CAGR of 6.8% from 2026 to 2033, driven by increasing use of injectable biologics and advanced immunotherapies. Intravenous and subcutaneous drug delivery systems are gaining importance for moderate to severe HIDS cases. These therapies provide faster onset of action and improved disease control compared to oral medications. Hospital-based administration ensures better monitoring of patient response. Rising adoption of IL-1 inhibitors delivered via injection is a major growth driver. Improved healthcare infrastructure is supporting wider use of parenteral therapies. Growing preference for targeted immune modulation is further accelerating segment expansion.

By End-Users

On the basis of end-users, the market is segmented into Hospitals, Specialty Clinics, Research & Academic Institutes, and Others. The Hospitals segment dominated the market with a share of 57.93% in 2025, due to strong diagnostic infrastructure, availability of multidisciplinary care, and high patient inflow for rare disease management. Hospitals are the primary centers for diagnosis, acute treatment, and long-term monitoring of HIDS patients. Availability of advanced laboratory testing and emergency care strengthens their dominance. Most biologic therapies are initiated and monitored in hospital settings. Government-funded healthcare systems also prioritize hospital-based rare disease treatment pathways. Hospitals often collaborate with research institutions for clinical trials and case studies. Their integrated care approach ensures better disease management outcomes.

The Specialty Clinics segment is expected to grow at the fastest CAGR of 6.9% from 2026 to 2033, driven by increasing establishment of rare disease and immunology-focused centers. These clinics offer specialized expertise in autoinflammatory disorders, improving diagnostic accuracy and personalized care. Growing patient preference for focused treatment environments is boosting adoption. Expansion of outpatient-based care models is reducing dependency on hospitals. Improved access to biologics and advanced therapies in specialty centers supports growth. Rising awareness among immunologists and rheumatologists is also contributing. Government initiatives supporting rare disease centers are further accelerating expansion.

By Distribution Channel

On the basis of distribution channel, the market is segmented into Hospital Pharmacy, Retail Pharmacy, and Others. The Hospital Pharmacy segment dominated the market with a share of 49.81% in 2025, due to direct dispensing of therapies during inpatient treatment and specialist consultations. Hospital pharmacies ensure immediate availability of corticosteroids, biologics, and supportive medications for HIDS patients. Integration with hospital treatment protocols strengthens their dominance. Most rare disease treatments are initiated within hospital settings under medical supervision. Hospital pharmacies also support controlled distribution of high-cost biologics. Strong procurement systems and insurance coverage further reinforce their position. Their role in emergency care and acute flare management is critical.

The Retail Pharmacy segment is expected to witness the fastest CAGR of 6.5% from 2026 to 2033, driven by increasing outpatient management and long-term prescription access. Improved availability of maintenance therapies outside hospitals is expanding retail pharmacy usage. Patients prefer retail channels for convenience and repeat prescriptions. Expansion of pharmacy networks in emerging economies supports accessibility. Growing awareness of chronic management needs is increasing demand. Digital prescription systems are improving medication distribution efficiency. Rising healthcare decentralization is further driving segment growth.

Hyperimmunoglobulin D Syndrome (HIDS) Treatment Market Regional Analysis

North America dominated the Hyperimmunoglobulin D Syndrome (HIDS) Treatment Market and accounted for the largest revenue share of 39.26% in 2025, supported by advanced healthcare infrastructure, strong rare disease awareness programs, robust genetic screening capabilities, and high adoption of biologic and targeted immunotherapies. The region also benefits from favorable orphan drug reimbursement frameworks, well-established clinical research networks, and early access to innovative immunology treatments, which collectively strengthen its leadership position in the global market.

U.S. Hyperimmunoglobulin D Syndrome (HIDS) Treatment Market Insight

The U.S. HIDS treatment market is witnessing strong growth due to rising investments in rare disease diagnosis, precision medicine, and biologic therapies targeting autoinflammatory conditions. The presence of advanced genomic testing facilities and next-generation sequencing (NGS) adoption is improving early detection rates of HIDS and related periodic fever syndromes. In addition, strong participation of pharmaceutical companies in orphan drug development and increasing clinical trial activity for IL-1 inhibitors are driving market expansion. Growing awareness among healthcare professionals and patient advocacy groups is also improving diagnosis-to-treatment timelines across the country.

Europe Hyperimmunoglobulin D Syndrome (HIDS) Treatment Market Insight

The Europe HIDS treatment market remains a key regional contributor, driven by strong public healthcare systems, established rare disease registries, and increasing focus on immunology-based research. Countries such as Germany, France, and the Netherlands are actively investing in rare disease networks that improve early diagnosis and patient management. Widespread access to biologics and supportive reimbursement policies further enhance treatment adoption. In addition, Europe’s strong emphasis on collaborative research programs and cross-border clinical studies continues to strengthen its position in the global HIDS treatment landscape.

U.K. Hyperimmunoglobulin D Syndrome (HIDS) Treatment Market Insight

The U.K. HIDS treatment market is experiencing steady growth supported by National Health Service (NHS)-backed rare disease initiatives and expanding genomic screening programs. The implementation of national rare disease strategies and improved access to whole-exome sequencing is enabling earlier identification of autoinflammatory disorders. Increasing adoption of biologics in specialist immunology centers and strong collaboration between academic institutions and pharmaceutical companies are further driving market development. In addition, growing patient awareness and referral networks are improving disease recognition rates across the country.

Germany Hyperimmunoglobulin D Syndrome (HIDS) Treatment Market Insight

The Germany HIDS treatment market is expanding steadily due to strong healthcare infrastructure, advanced laboratory diagnostics, and increasing focus on precision immunology. German hospitals and university research centers are actively involved in rare disease studies, improving clinical understanding of HIDS. High adoption of biologic therapies and strong reimbursement support for orphan drugs further strengthen market growth. In addition, Germany’s leadership in biomedical research and its robust pharmaceutical manufacturing ecosystem are supporting innovation in autoinflammatory disease treatments.

Asia-Pacific Hyperimmunoglobulin D Syndrome (HIDS) Treatment Market Insight

The Asia-Pacific HIDS treatment market is expected to witness rapid growth, projected to register a CAGR of 7.2% from 2026 to 2033, driven by rising healthcare awareness, improving rare disease diagnosis rates, and expanding healthcare infrastructure. Increasing access to advanced biologics and immunology-based treatments is supporting market adoption across countries such as China, India, and Japan. Government initiatives to strengthen rare disease frameworks, along with growing investment in genomic medicine and hospital modernization, are further accelerating regional market expansion. Rising participation in global clinical trials is also improving treatment availability and awareness.

Japan Hyperimmunoglobulin D Syndrome (HIDS) Treatment Market Insight

The Japan HIDS treatment market is growing steadily due to advanced healthcare systems, strong emphasis on early diagnosis, and increasing adoption of genomic medicine. Hospitals and research institutions are integrating next-generation sequencing technologies to improve identification of rare autoinflammatory diseases. Japan’s pharmaceutical industry is also actively investing in biologics and targeted immunotherapies. In addition, growing awareness among clinicians and the integration of precision medicine approaches are further enhancing disease management outcomes.

China Hyperimmunoglobulin D Syndrome (HIDS) Treatment Market Insight

The China HIDS treatment market is expanding rapidly, driven by improving healthcare infrastructure, increasing rare disease awareness, and rising adoption of advanced diagnostic technologies. Government initiatives to strengthen rare disease registries and expand insurance coverage for orphan drugs are supporting treatment accessibility. Growing investment in hospital modernization and biotechnology research is accelerating the use of biologics and immunomodulatory therapies. In addition, China’s expanding clinical research ecosystem and increasing participation in global drug development programs are positioning it as a key growth market in the Asia-Pacific region.

Hyperimmunoglobulin D Syndrome (HIDS) Treatment Market Share

The Hyperimmunoglobulin D Syndrome (HIDS) Treatment industry is primarily led by well-established companies, including:

• Novartis AG (Switzerland)
• Pfizer Inc. (U.S.)
• Sanofi S.A. (France)
• Roche Holding AG (Switzerland)
• AbbVie Inc. (U.S.)
• Johnson & Johnson (U.S.)
• Bristol Myers Squibb (U.S.)
• Amgen Inc. (U.S.)
• AstraZeneca plc (U.K.)
• Takeda Pharmaceutical Company Limited (Japan)
• Regeneron Pharmaceuticals, Inc. (U.S.)
• Swedish Orphan Biovitrum AB (Sobi) (Sweden)
• Kiniksa Pharmaceuticals (U.S.)
• BioCryst Pharmaceuticals (U.S.)
• Vertex Pharmaceuticals (U.S.)
• Merck & Co., Inc. (U.S.)
• Eli Lilly and Company (U.S.)
• GlaxoSmithKline plc (GSK) (U.K.)
• Bayer AG (Germany)
• Boehringer Ingelheim (Germany)
• CSL Limited (Australia)
• Teva Pharmaceutical Industries Ltd. (Israel)
• Ipsen S.A. (France)
• Alnylam Pharmaceuticals, Inc. (U.S.)
• Alexion Pharmaceuticals (U.S.)
• Grifols S.A. (Spain)
• Recordati S.p.A. (Italy)
• Chugai Pharmaceutical Co., Ltd. (Japan)
• Otsuka Pharmaceutical Co., Ltd. (Japan)
• Dr. Reddy’s Laboratories Ltd. (India)
• Sun Pharmaceutical Industries Ltd. (India)
• Biogen Inc. (U.S.)
• Thermo Fisher Scientific Inc. (U.S.)

Latest Developments in Hyperimmunoglobulin D Syndrome (HIDS) Treatment Market

• In November 2024, an international consortium of autoinflammatory disease experts published updated SHARE recommendations and a comprehensive clinical overview for Mevalonate Kinase Deficiency (MKD), which includes Hyperimmunoglobulin D Syndrome (HIDS). The updated recommendations emphasized earlier genetic diagnosis, optimized use of IL-1 inhibitors, and standardized treatment pathways for patients with HIDS/MKD. The publication is expected to improve clinical management and support wider adoption of targeted biologic therapies globally
• In April 2024, researchers from the Amsterdam University Medical Centers published new findings on the molecular and cellular mechanisms of mevalonate kinase deficiency. The study provided deeper insights into inflammatory pathways involved in HIDS and highlighted potential opportunities for the development of next-generation targeted therapies, supporting ongoing innovation in rare autoinflammatory disease treatment
• In August 2023, a long-term clinical report demonstrated sustained efficacy of the IL-1 inhibitor Canakinumab in a patient with Hyperimmunoglobulin D Syndrome. The study reported successful long-term remission over five years without significant safety concerns, reinforcing growing physician confidence in biologic therapies for managing recurrent inflammatory attacks associated with HIDS
• In May 2025, the National Organization for Rare Disorders (NORD) updated its clinical resource on Mevalonate Kinase Deficiency (MKD)/HIDS, highlighting advances in biologic treatment approaches, disease awareness, and patient management. The update reflects increasing clinical recognition of HIDS and growing utilization of targeted immunotherapies in rare disease care pathways
• In May 2025, the European Medicines Agency reaffirmed the use of Ilaris (canakinumab) for patients with Hyperimmunoglobulin D Syndrome/Mevalonate Kinase Deficiency as part of its updated medicine information. The continued regulatory support for canakinumab underscores the growing importance of IL-1 blockade therapies in the treatment of rare periodic fever syndromes, including HIDS
• In October 2025, clinicians reported a rare HIDS/MKD case from Tanzania that was successfully diagnosed through genetic evaluation, highlighting expanding awareness and diagnostic capabilities for rare autoinflammatory disorders in emerging healthcare markets. The case underscores the increasing global emphasis on genetic testing and earlier diagnosis of HIDS, which is expected to support treatment market growth over the coming years

SKU-52647